2019 年于阿姆斯特丹大学学术医学中心得博士学位,同年加入到奥胡斯大学生物医学系进行博士
后训练, 2023 年以“南山学者”加入广州医科大学生科院。主要从事病毒载体研究,基因编辑工具
的开发和优化,HIV 和遗传性疾病的基因治疗等。工作成果以第一作者发表在在 Nucleic Acids Research,
Molecular Therapy, JBC, Molecular-Therapy Nucleic Acids 等 杂 志 上 , 并 以 参 与 作 者 在 Nature
Immunology, Leukemia, Genome Research 等杂志发表论文。
部分论文
1. Gao Z, Ravendran S, Mikkelsen N, et al. A truncated reverse transcriptase enhances prime editing
by split AAV vectors. Molecular Therapy, 2022 (9).
2. Gao Z
, van der Velden YU
, Fan M, van der Linden CA, Vink M, Herrera-Carrillo E, Berkhout B.
Engineered miniature H1 promoters with dedicated RNA polymerase II or III activity. Journal Biology
Chemistry, 2021
3. Gao Z
, Fan M
, Das AT, et al. Extinction of all infectious HIV in cell culture by the
CRISPR-Cas12a system with only a single crRNA. Nucleic Acids Research, 2020(10).
4. Herrera-Carrillo E*, Gao Z*, Berkhout B. CRISPR therapy towards an HIV cure. Brief in Functional
Genomics, 2020 (3). (co-first)
5. Gao Z, Herrera-Carrillo E, Berkhout B. A single H1 promoter can drive both guide RNA and
endonuclease expression in the CRISPR-Cas9 system. Mol Ther Nucleic Acids, 2019.
6. Gao Z, Berkhout B, Herrera-Carrillo E. Boosting AgoshRNA activity by optimized 5'-terminal
nucleotide selection. RNA Biology, 2019(7).
7. Gao Z, Herrera-Carrillo E, Berkhout B. RNA polymerase II activity of type 3 Pol III promoters. Mol
Ther Nucleic Acids, 2018.
8. Gao Z, Herrera-Carrillo E, Berkhout B. Delineation of the exact transcription termination signal for
type 3 polymerase III. Mol Ther Nucleic Acids, 2018.
1. CRISPR/Cpf1-based gene editing, gene activation, and base editing in hematopoietic stem cells,丹麦
Lundbeck Foundation 基金(R303-2018-3571),2019.6-2022.5, 240 万丹麦克朗,主持,结题。
2. 广州医科大学 2023 年高层次人才经费项目,2023.3-2028.2,300 万,主持。